TRK-820 Study in Subjects on Hemodialysis With or Without Uremic Pruritus
Status:
Completed
Trial end date:
2017-07-01
Target enrollment:
Participant gender:
Summary
This study is a 2-part study.
Part A is a single-dose, open-label study design to determine the PK, safety and tolerability
of 5 μg TRK-820 oral administration in subjects with end-stage renal disease (ESRD) who
require hemodialysis.
Part B is a multiple dose, open-label study design to determine the PK, PD, safety and
tolerability of multiple doses in subjects with ESRD who require hemodialysis with refractory
uremic pruritus (UP). Each subject will receive 3 doses of TRK-820 (2.5, 5 and 10 μg).